There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics (VBLT) and Clearside Biomedical (CLSD) with bullish sentiments.
Vascular Biogenics (VBLT)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Vascular Biogenics today and set a price target of $5.00. The company’s shares closed last Tuesday at $2.25.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 72.9% and a 69.9% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Adverum Biotechnologies.
Currently, the analyst consensus on Vascular Biogenics is a Strong Buy with an average price target of $5.50, representing a 137.1% upside. In a report issued on June 3, Roth Capital also maintained a Buy rating on the stock with a $7.00 price target.
See today’s analyst top recommended stocks >>
Clearside Biomedical (CLSD)
JMP Securities analyst Jonathan Wolleben maintained a Buy rating on Clearside Biomedical today and set a price target of $9.00. The company’s shares closed last Tuesday at $3.81.
According to TipRanks.com, Wolleben is a 4-star analyst with an average return of 28.4% and a 55.6% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Strongbridge Biopharma, and Larimar Therapeutics.
Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $8.00, implying a 100.1% upside from current levels. In a report issued on June 2, Wedbush also reiterated a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
